Study explores patterns and prognostic implications of immune-related adverse events in cancer patients on immune checkpoint inhibitors.
- A recent study by researchers from Massachusetts General Hospital and Harvard Medical School examined immune-related adverse events in cancer patients undergoing immune checkpoint inhibitor therapy.
- The study involved 13,000 patients and found that certain immune-related adverse events tend to co-occur, such as those affecting the eyes, skin, and gastrointestinal system.
- The research identified seven patient clusters with different patterns of immune-related adverse events, impacting patient survival outcomes.
- Patients experiencing endocrine and cutaneous immune-related adverse events had improved survival, while those with respiratory and neurologic events had worse outcomes.
- The findings offer valuable insights for clinicians in identifying patient clusters early in treatment to guide treatment decisions and provide a deeper understanding of immune-related adverse events.
Source link
Oncology, Immunology, Pharmacists, Infectious Diseases, Dermatology